ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Dual Impact Channel
  2. Reliability Carried the Day for Healthcare Sector
Dual Impact Channel
Share

Reliability Carried the Day for Healthcare Sector

Tom LydonJan 03, 2023
2023-01-03

With just two trading days left in 2022, it’s safe to say the healthcare sector was significantly less bad than the broader market. As of December 27, the S&P 500 Health Care Index was down just 2.2% year-to-date compared to nearly 19% for the S&P 500.

That could be a sign that exchange traded funds such as the IQ Healthy Hearts ETF (HART ) could be poised for better things in the new year. Focusing on what supported outperformance in 2022, the healthcare sector was bolstered by some of its largest constituents, including several HART member firms.

Among HART’s advantages entering 2023 is that aside from a 5.2% allocation to Pfizer (NYSE:PFE), the ETF isn’t heavily dependent on coronavirus vaccine makers. Regarding Pfizer, that company has a deep pipeline and several years of patent protection confirming it’s about much more than the COVID-19 vaccine.

This “was the year where companies that didn’t benefit that much from Covid-19 tended to outperform. In 2021, the biggest gainers were, naturally enough, the vaccine-makers, with Moderna and BioNTech more than doubling in value while Pfizer added 60%. All three vaccine-makers are down this year, as a return to normal benefits the rest of the sector,” reported David Wainer for the Wall Street Journal.

Another reason HART could be a viable consideration for tactical investors in 2023 is the specter of more market volatility — something healthcare stocks can help investors grapple with. Year-to-date, the S&P 500 Health Care Index is about 400 basis points less volatile than the S&P 500.

Add to that, not only are HART components such as Novartis (NYSE:NVS), AstraZeneca (NASDAQ:AZN), Eli Lilly (NYSE:LLY), and Dow component Johnson & Johnson (NYSE:JNJ) not known for extreme bouts of volatility, but they are known for quality traits, including dividend growth.

HART could also be in focus in 2023 amid expectations that consolidation will return to the healthcare sector in earnest, which is relevant to the ETF because many of its healthcare holdings are cash-rich companies with appetites for acquisitions when the right deal presents itself.

“In all, next year could bring M&A deal value in the pharma and life-sciences space to somewhere in the range of $225 billion to $275 billion, PricewaterhouseCoopers wrote in a report. With so much dry powder and plenty of targets to look at, deal-making next year looks set to heat up,” according to the Journal.

For more news, information, and strategy, visit the Dual Impact Channel.

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X